Eventide Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Eventide Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8M	Sell	1,327,536 -186,422	-12%	-$2.88M	0.32%	98
2026 Q1	$21M	Buy	1,513,958 +810	+0.1%	+$11.4K	0.35%	101
2025 Q4	$18.3M	Buy	1,513,148 +648	+0%	+$8.8K	0.29%	107
2025 Q3	$20.6M	Buy	+1,512,500	New	+$14.2M	0.34%	95
2024 Q1	–	Sell	-1,116,837	Closed	-$16.4M	–	160
2023 Q4	$16.4M	Hold	1,116,837	–	–	0.27%	97
2023 Q3	$20.4M	Hold	1,116,837	–	–	0.37%	81
2023 Q2	$24.1M	Buy	1,116,837 +658,783	+144%	+$17.8M	0.41%	76
2023 Q1	$13.4M	Buy	458,054 +208,054	+83%	+$7.23M	0.25%	109
2022 Q4	$9.24M	Buy	+250,000	New	+$8.87M	0.18%	110

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Eventide Asset Management's AMLX Position: Q2 2026 in Review

Eventide Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 12% in Q2 2026, selling an estimated $2.88M and leaving 1,327,536 shares worth $23.8M. The position accounts for 0.32% of the portfolio, ranked #98.

Eventide Asset Management first reported a position in AMLX in Q4 2022 and has held it in 9 quarters since. The position peaked at $24.1M in Q2 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Eventide Asset Management held 1,327,536 shares of Amylyx Pharmaceuticals worth $23.8M as of Q2 2026.
Eventide Asset Management sold 186,422 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $2.88M.
Amylyx Pharmaceuticals made up 0.32% of Eventide Asset Management's portfolio in Q2 2026, its #98 holding.
Eventide Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Eventide Asset Management's Amylyx Pharmaceuticals position peaked at $24.1M in Q2 2023.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.